The estimated Net Worth of Jose E Rivera is at least $4.24 Million dollars as of 1 April 2021. Mr. Rivera owns over 97,001 units of Intellia Therapeutics Inc stock worth over $3,604,278 and over the last 8 years he sold NTLA stock worth over $0. In addition, he makes $637,649 as Executive Vice President and General Counsel at Intellia Therapeutics Inc.
Jose has made over 13 trades of the Intellia Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 97,001 units of NTLA stock worth $1,213,483 on 1 April 2021.
The largest trade he's ever made was exercising 109,000 units of Intellia Therapeutics Inc stock on 1 February 2021 worth over $1,055,120. On average, Jose trades about 15,660 units every 16 days since 2017. As of 1 April 2021 he still owns at least 178,077 units of Intellia Therapeutics Inc stock.
You can see the complete history of Mr. Rivera stock trades at the bottom of the page.
Jose E. Rivera J.D. serves as Executive Vice President, General Counsel of the Company. Previously served as our chief operating officer and chief legal officer from April 2015 to January 2017. He joined Intellia in July 2014 as our general counsel and chief talent officer. Prior to joining Intellia, Mr. Rivera was the vice president, chief ethics and compliance officer at AbbVie from its spin-out from Abbott in January 2013 until September 2013. From 1996 to 2012, Mr. Rivera was a member of Abbott’s legal division serving in a number of positions of increasing responsibilities, including leading various legal groups as division vice president and associate general counsel, such as Abbott’s global intellectual property group, intellectual property litigation department, legal regulatory department and litigation department. Mr. Rivera is a member of the board of directors of the North Suburban Legal Aid Clinic (Illinois). Mr. Rivera received his B.A. in economics from Boston College and his J.D. from Harvard Law School.
As the Executive Vice President and General Counsel of Intellia Therapeutics Inc, the total compensation of Jose Rivera at Intellia Therapeutics Inc is $637,649. There are 4 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.
Jose Rivera is 54, he's been the Executive Vice President and General Counsel of Intellia Therapeutics Inc since 2017. There are 11 older and 7 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
Jose's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE, MA, 02139.
Over the last 8 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela, and Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: